Karyopharm Therapeutics Inc (KPTI)

Currency in USD
6.220
+0.630(+11.27%)
Closed·
6.2200.000(0.00%)
·
KPTI Scorecard
Full Analysis
Operates with a significant debt burden
KPTI is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
5.4906.400
52 wk Range
3.51016.950
Key Statistics
Prev. Close
6.22
Open
5.59
Day's Range
5.49-6.4
52 wk Range
3.51-16.95
Volume
136.35K
Average Volume (3m)
155.69K
1-Year Change
-49.07%
Book Value / Share
-27.65
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
KPTI Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
25.917
Upside
+316.67%
Members' Sentiments
Bearish
Bullish
ProTips
High shareholder yield
Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy

Karyopharm Therapeutics Inc Company Profile

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It also developing Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating Myelodysplastic Neoplasms, as well as verdinexor, KPT-9274, and IL-12 compounds. In addition, the company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for the diagnosis, treatment, and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. Further, the company has a collaboration with Bristol Myers Squibb company to evaluate novel cereblon E3 ligase modulator agent mezigdomide in combination with Selinexor in patients with relapsed/refractory multiple myeloma. Karyopharm Therapeutics Inc. was incorporated in 2008 and is headquartered in Newton, Massachusetts.

Employees
279

Karyopharm Therapeutics Inc SWOT Analysis


Pipeline Promise
Karyopharm's clinical trials in myelofibrosis and endometrial cancer could potentially double annual revenue, with data expected by early 2026
Financial Tightrope
Despite steady Xpovio sales, cash burn and delayed study timelines raise concerns about future funding needs and potential market challenges
Valuation Disconnect
Analysts see significant upside potential, with price targets ranging from $3 to $33, suggesting the stock may be undervalued given its pipeline prospects
Competitive Edge
Explore how Karyopharm's unique SINE compound technology positions it in the oncology market, with potential for expansion into multiple cancer indications
Read full SWOT analysis

Karyopharm Therapeutics Inc Earnings Call Summary for Q2/2025

  • Q2 2025 revenue declined to $37.9M from $42.8M YoY, despite 6% growth in XPOVIO sales; net loss of $37.3M or $4.32 per share
  • 20% workforce reduction announced to optimize costs; exploring strategic alternatives to address liquidity concerns with debt maturity in October 2025
  • Full-year 2025 revenue guidance of $140M-$155M; XPOVIO net product revenue expected between $110M-$120M
  • Three major data readouts anticipated in 2026 for pipeline advancements in myelofibrosis and endometrial cancer
  • Cash and equivalents down to $52M from $109.1M at end of 2024; financial health score of 1.92/5, labeled as 'FAIR' by analysts
Last Updated: 11/08/2025, 14:26
Read Full Transcript

Compare KPTI to Peers and Sector

Metrics to compare
KPTI
Peers
Sector
Relationship
P/E Ratio
−0.4x−0.5x−0.6x
PEG Ratio
−0.03−0.020.00
Price/Book
−0.2x2.4x2.6x
Price / LTM Sales
0.4x6.9x3.3x
Upside (Analyst Target)
221.5%314.4%40.1%
Fair Value Upside
Unlock15.9%5.3%Unlock

Analyst Ratings

5 Buy
2 Hold
0 Sell
Ratings:
7 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 25.917
(+316.67% Upside)

Earnings

Latest Release
Aug 11, 2025
EPS / Forecast
-4.32 / -0.1025
Revenue / Forecast
37.93M / 41.73M
EPS Revisions
Last 90 days

KPTI Income Statement

People Also Watch

2.050
VOR
+0.49%
1.180
TNYA
-6.35%
20.18
SRPT
-3.86%
462.14
MEDP
-0.17%
37.52
EXEL
-0.64%

FAQ

What Stock Exchange Does Karyopharm Trade On?

Karyopharm is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Karyopharm?

The stock symbol for Karyopharm is "KPTI."

What Is the Karyopharm Market Cap?

As of today, Karyopharm market cap is 53.76M.

What Is Karyopharm's Earnings Per Share (TTM)?

The Karyopharm EPS (TTM) is -14.62.

From a Technical Analysis Perspective, Is KPTI a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Karyopharm Stock Split?

Karyopharm has split 1 times.

How Many Employees Does Karyopharm Have?

Karyopharm has 279 employees.

What is the current trading status of Karyopharm (KPTI)?

As of 20 Aug 2025, Karyopharm (KPTI) is trading at a price of 6.22, with a previous close of 6.22. The stock has fluctuated within a day range of 5.49 to 6.40, while its 52-week range spans from 3.51 to 16.95.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.